Author:
Kulkarni Suyash S.,Shetty Nitin Sudhakar,Mishra Shashank,Narayan David
Reference33 articles.
1. Kumar A, Srivastava DN, Chau TTM, Long HD, Bal C, Chandra P, et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. Radiology. 2007 May;243(2):509–19.
2. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND. Neoangiogenesis and sinusoidal “capillarization” in dysplastic nodules of the liver. Am J Surg Pathol. 1998 Jun;22(6):656–62.
3. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol Off J Am Soc Clin Oncol. 1987 Nov;5(11):1836–40.
4. Konno T, Maeda H, Yokoyama I, Iwai K, Ogata K, Tashiro S, et al. Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, smancs, for hepatocellular carcinoma. Gan To Kagaku Ryoho. 1982 Nov;9(11):2005–15.
5. Covey AM, Brody LA, Maluccio MA, et al. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology. 2002;224(2):542–7.